115 related articles for article (PubMed ID: 21944536)
1. Surgery after neoadjuvant chemotherapy for locally advanced extrapulmonary poorly differentiated neuroendocrine cancer.
Lessing Y; Ben-Haim M; Lahat G; Nackache R; Klausner JM; Shmueli E; Lubezky N
Am Surg; 2011 Aug; 77(8):1102-4. PubMed ID: 21944536
[No Abstract] [Full Text] [Related]
2. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy?
Hackert T; Ulrich A; Büchler MW
Adv Surg; 2017 Sep; 51(1):1-10. PubMed ID: 28797331
[No Abstract] [Full Text] [Related]
3. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters.
Crippa S; Partelli S; Bassi C; Berardi R; Capelli P; Scarpa A; Zamboni G; Falconi M
Surgery; 2016 Mar; 159(3):862-71. PubMed ID: 26602841
[TBL] [Abstract][Full Text] [Related]
4. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
5. Curative surgery after neoadjuvant chemotherapy in metastatic poorly differentiated neuroendocrine carcinoma.
Sørbye H; Westre B; Horn A
Eur J Surg Oncol; 2007 Dec; 33(10):1209-10. PubMed ID: 17350785
[No Abstract] [Full Text] [Related]
6. Neuroendocrine tumor of the gallbladder treated with neoadjuvant chemotherapy and surgery.
Smith JL; Davis BR
Am Surg; 2014 Mar; 80(3):318-20. PubMed ID: 24666880
[No Abstract] [Full Text] [Related]
7. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.
Crippa S; Partelli S; Belfiori G; Palucci M; Muffatti F; Adamenko O; Cardinali L; Doglioni C; Zamboni G; Falconi M
World J Gastroenterol; 2016 Dec; 22(45):9944-9953. PubMed ID: 28018101
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant therapy for pancreatic cancer.
Lowy AM
J Gastrointest Surg; 2008 Sep; 12(9):1600-8. PubMed ID: 18259825
[TBL] [Abstract][Full Text] [Related]
9. Clinical recommendations on the treatment of neuroendocrine carcinoma of the larynx: A meta-analysis of 436 reported cases.
van der Laan TP; Plaat BE; van der Laan BF; Halmos GB
Head Neck; 2015 May; 37(5):707-15. PubMed ID: 24596175
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy in stage III breast cancer.
Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD
Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927
[TBL] [Abstract][Full Text] [Related]
11. [A case of a neuroendocrine carcinoma in the minor papilla].
Ha DW; Kim GH; Kim DU; Bae MJ; Kim BW; Jeon HK; Park DY; Seo HI
Korean J Gastroenterol; 2011 Sep; 58(3):144-8. PubMed ID: 21960102
[TBL] [Abstract][Full Text] [Related]
12. Nonfunctioning neuroendocrine pancreatic tumors: our experience and management.
Nomura N; Fujii T; Kanazumi N; Takeda S; Nomoto S; Kasuya H; Sugimoto H; Yamada S; Nakao A
J Hepatobiliary Pancreat Surg; 2009; 16(5):639-47. PubMed ID: 19365596
[TBL] [Abstract][Full Text] [Related]
13. Preoperative chemoradiation for resectable and locally advanced adenocarcinoma of the pancreas.
Evans DB
J Gastrointest Surg; 2001; 5(1):2-5. PubMed ID: 11370617
[No Abstract] [Full Text] [Related]
14. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
15. Management of Small Nonfunctioning Pancreatic Neuroendocrine Tumors: An Analysis of the US Surveillance, Epidemiology, and End Results Database.
Ji S; Liu M; Xia H; Ye Z; Xu X; Yu X; Zhuo Q
Pancreas; 2021 Jan; 50(1):e8-e10. PubMed ID: 33370038
[No Abstract] [Full Text] [Related]
16. Role of adjuvant chemoradiotherapy for duodenal cancer: a single center experience.
Kim K; Chie EK; Jang JY; Kim SW; Oh DY; Im SA; Kim TY; Bang YJ; Ha SW
Am J Clin Oncol; 2012 Dec; 35(6):533-6. PubMed ID: 21659832
[TBL] [Abstract][Full Text] [Related]
17. [Stereotactic ablative body radiotherapy (SABRT) for locally advanced pancreatic cancer. Case report and review of literature].
Földi G; Zongor Z; Polgár C; Stelczer G; Madaras B; Andi J; Lövey J
Magy Onkol; 2017 Dec; 61(4):387-392. PubMed ID: 29257159
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F
Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979
[TBL] [Abstract][Full Text] [Related]
19. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of radical resection for locally advanced duodenal adenocarcinoma.
Bucher P; Gervaz P; Morel P
Hepatogastroenterology; 2005; 52(66):1727-9. PubMed ID: 16334766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
